2024-519327-20-00
Recruiting
Phase 1
A study to test how well multiple doses of BI 3810477 are tolerated by healthy adults.
Boehringer Ingelheim International GmbH1 site in 1 country48 target enrollmentStarted: April 3, 2025Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 48
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer2022-502125-17-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.14
Recruiting
Phase 1/2
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors2022-503066-74-00Bioinvent International AB84
Not yet recruiting
Phase 2
Study that aims to investigate how effective and safe the use of a novel modified release tablet formulation of Colesevelam hydrochloride-MMX is for patients with idiopathic bile acid diarrhoea (BAD), randomly allocated to 2 different dose regimens of the active product or to the inactive placebo formulation.2024-511993-55-00Cosmo Technologies Limited120
Recruiting
Phase 1
A study to test how well different doses of BI 3804379 are tolerated by healthy people2024-513549-36-01Boehringer Ingelheim International GmbH106
Not yet recruiting
Phase 2
A study to test whether BI 1815368 helps people with an eye condition called diabetic macular edema2024-520384-14-00Boehringer Ingelheim International GmbH193